Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

MSL Talk

Interim Impact: The Rise of “Fractional” Medical Affairs Roles in Pharma’s New Reality

Aug 19, 202537 minVideo
ShareXLinkedInFacebookWhatsAppEmail

In this episode, Tom Caravela and Daniel Snyder explore the rise of fractional medical affairs roles in the post-COVID era. They define interim and fractional positions, highlighting how they benefit both job seekers and companies. The discussion covers the increase in these roles, company utilization of interim talent, disadvantages, and compensation expectations, offering negotiation tips for candidates. They also discuss the future of fractional staffing, market trends, and the gig economy's impact on pharma and biotech. The episode ends with cost-effective strategies and gratitude to the audience.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show.

0:01Hey, guys. Welcome to the podcast. I have a returning repeat guest today, Daniel Snyder. Daniel, welcome to the show, my friend. Alright, Tom. Always a pleasure to chat with you and your great audience about medical affairs and whatever path it takes. Always enjoy it. Thank man. Having me. I'm excited about this one. So, guys, Daniel's been on the show before. We know each other for a long time. He brought up the idea of talking about, the rise of fractional medical affairs roles in

0:37pharma. We're gonna I think this is a great topic. I think you guys are gonna appreciate it's very timely. I think you're gonna appreciate this. Before we get into a couple announcements, don't forget right now is the time to sign up for Fierce Pharma Week, which is coming up September, and that's gonna be in Philadelphia at the Pennsylvania Convention Center. This used to be mass east. It's now fierce pharma week. It's a bigger event that has a couple of different tracks.

1:11There's medical affairs, so, obviously, there's a track for you guys. And then there's a, a marketing and a PR and a BD BD focus as well. So go to Fierce Pharma Week, and then literally go to Google. Type in Fierce Pharma Week. It'll come up. When you register, type in the code m s l t a l k, and you'll get 25% off. So definitely love to see you out there.

1:41Don't miss out. It's, registration's gonna close-up soon, so definitely check that out. And one more quick announcement. It's the second year anniversary of the Aspire MSL program for so if there's any aspiring MSLs that are interested in checking out the coaching program that we have for aspiring MSLs, you definitely wanna take advantage now because we're relaunching the program with a bunch of new features, a brand new chatbot or an updated Supermira chatbot, which is gonna be

2:12awesome. There's gonna be a lot of new AI stuff in there, interview preparation stuff, and then the main course. So you go to mslmastery.com. And then when you get to the home page, just click on the aspire button. That'll give you all the information, and do it now because the price is gonna increase when we relaunch it. So right now, it's August. I would try to get this done before September so you could take advantage before the price goes up. Alright, Daniel. Let's get into it. As I mentioned, we're gonna be talking about fractional rolls.

2:46So what let's start with the definition. So what would you say is the definition, or how would you define what would be called either interim or fractional roles in medical affairs? And then how are they different from traditional full time roles? Yeah, Tom. So the interim, the fractional, contract based, roles, they're they're kinda synonymous, and they they mean part time.

3:18There's Mhmm. Very specific deliverables that are requested, and you come in as an expert if you if you're involved with this type of work. I personally happen to be. I'm, for the first time in my career, I've been downsized a little over a year ago, and I wanna stay busy as I look for a new full time role. And I was very fortunate to have been, approached by a couple of CEOs who was were

3:51aware of me and knew what I, was capable of, helped them out, and it's it's just kind of, started to grow. Again, I keep looking for a new full time job, but this is something that's keeping me busy and keeping my skills well honed and so forth. So it's to your question, it is project based, part time, clear deliverable, or a clear period

4:21of time by which you provide your scientific, your professional, let's just say, medical affairs expertise to the company, and you you have, like I said, particular deliverables to provide, and and you work with that organization until those deliverables are are met. Yeah. That answers your question. And it's this isn't a new concept. I mean, this has been going on for many, many years.

4:53It's just what what we're seeing is that the the like, the terminology has changed a little bit because this word fractional is it's really taken off. It's become a big thing. Yeah. Why why would you say this has starting to become more popular, and why the rise in fractional positions right now in pharma? Very simply, Tom, pharma is post COVID gone through a an adjustment period, a redefining

5:27moment where I think during COVID, what happened was there there were the talent wasn't as as abundant as it is now, and there was a lot of probably overhiring going on during that period of time. And now there's been a bit of a reckoning where pharmaceutical biotech med tech organizations have had to really take a hard look at their pipelines, really rationalize their business

6:02models, streamline. And then on top of it, as we're all aware of, there are some economic uncertainties. Most recently from the change in administration, you have tariffs, you have cutbacks in r and d funding, you have an a quest to become equal in terms of O US paying for drugs as opposed to The United States paying the bulk of the development of drugs and

6:35so forth. So as you can imagine, with that degree of uncertainty, VCs, private equity are probably looking at pharma as potentially a riskier investment. So you see these clinical stage biotech companies who are pretty pretty confident in drumming up the requisite money that they need for their runway to develop the the, the early phase assets and so forth, having to really think about their spend rate, their burn rate,

7:10and really rationalize how do we get the critical things that we need to get done, but to do it without the type of money that they're probably used to with other in the better times that, pharma, biotech, and med tech found themselves in. So economic headwinds in a nutshell, and then the realization that critical things need to get done, and how do we do that without a permanent hire because of the uncertainty

7:41associated with? Can we get things done but not take up an FTE to do that? Right. And and as as you're well aware, there's been a lot of layoffs over the last couple years. I'm I'm a consequence of it. First time in my over thirty year career. And a lot of my friends and colleagues have experienced this recently. And this is a really good I call it a gig to to keep things going, keep things interesting,

8:13keep busy, and this gig economy is is picking up steam. So It's a good way to put it. And you're I mean, obviously, anyone listening to this is familiar with the fact that there have been lots of layoffs. They may have been affected by layoffs or know somebody that's been affected by layoffs. It's over the course of the past two years, pretty much unprecedented in our industry. But here's the thing. Companies still need to get things done.

8:46They still have to drive strategy, and they still are responsible for doing business and getting things done. So how how have you seen companies utilize interim and fractional talent to help drive strategy? What maybe it's post layoff or, you know, when maybe they they have a bit of a deficit. Absolutely. Well, speaking from firsthand experience, I've I've been brought into organizations.

9:17I've been tapped by chief development officers, CEOs, and chief medical officers who are rather forward thinking, and they realize that, okay. I need to move this program forward. I don't have the luxury of bringing in, let's just say, a head of medical affairs, but I know there are things that need to get done. We're at a critical tipping point. We're we're transitioning from phase one. We're gearing up to do phase two, and I just and they have this feeling that, hey.

9:52I don't wanna miss incorporating something into our next pivotal program. Let's bring in somebody who's done these types of things and provide us with a consultancy so that we don't miss the boat on incorporating things that we should incorporate at this critical stage of our clinical stage of development and so forth. So I've been brought in and developed a soup to nuts strategic tactical medical affairs plan. I've also been brought in to develop an integrated evidence generation plan, and this

10:27kind of folds in very nicely into the clinical development process, and I've advised companies, you might wanna consider incorporating this into your protocol because it could pave the way of you building in real world evidence. And why is that important? Well, it's important at the early stages to think about the end in mind. Mhmm. What are the things that you're going to, for lack of better term, leverage when you get your

10:59clinical data, when you're in that peri launch phase and you're starting to speak with payers, you wanna have as much critical evidence, not just about your your program, your your assets from a clinical stage perspective and then from your clinical program, but how does it compare to what's already on formulary? And that's a tough thing to do pre PDUFA date, but there are certain things that you can incorporate into your, your pivotal program that would allow you to do some differentiation

11:34and so forth. And having that type of information upfront in that perilaunch phase can really make a difference once you get the approval and then you launch the product and so forth. So I really applaud those forward thinking c suite leaders who who who know what they don't know or they they they're very forthright and and and and honest and say, I I think there's probably things we should think about. And you bring in a seasoned expert who's done all these things, and you get some critical

12:12perspective before you lock and load into your clinical program. So, hopefully does that give you some perspective on that question, Tom? Yeah. Yeah. Absolutely. You know, it's it's I actually have so many questions because there's there's so much nuance to this. So, like, people that are listening right now that are in transition and considering their next move, interviewing for positions.

12:44Should they, and how would this be a good idea or an opportunity to bridge the gap considering something fractional or or interim. But can you talk about that a little bit? Absolutely. So it's a tough market out there. Let's all be honest. And there's so much talent out there as a consequence as you pointed out with the downsizing and the layoffs and so forth. So there's very few opportunities, and there's a lot of talent out there.

13:16But given the economic uncertainty, it provides opportunity for those who are willing to leverage their network and to do the requisite research to find those types of companies who may benefit from their experience and so forth. So it really for those individuals who are willing to kinda shift gears and still remain in the game but do it slightly differently as opposed to working for a company and taking

13:50more of an entrepreneurial spirit to it, it can be it it it can be refreshing. It's it's a bit daunting, quite frankly, from a a business development perspective, but being able to still work within medical affairs and provide solutions to companies can be very gratifying. And I have a number of colleagues who still haven't landed a a new full time position who

14:20are starting to, you know, dip their toe into this consulting, this fractional, this interim, this contract based work. And it's kind of opening their eyes to the possibilities. It's keeping them busy. It's extending their network, and they're able to establish a track record of providing these deliverables, which they can work into the interview process as they continue to look for

14:52another full time job. I know it's for me personally, it's opened up a whole new therapeutic area for me, And I'm leveraging that in my interviews for full times positions because then it it broadens the the opportunity for a particular, position that I otherwise wouldn't have had the opportunity, to, to apply for because of the specificity of the job description.

15:26Know, nowadays, with all these, very talented folks out there, companies are in the position of getting very specific about what they want, from a prior experience for a a new position that needs to be filled and so forth. So having the latitude to work for a company in a a fractional basis and provide value to that company has the the potential to expand your therapeutic expertise.

15:56And I I I I benefited from that. I mean, it's also a resume builder. Yes. Absolutely. This is a a way to to bridge a gap. It you know, you you kinda if you can find a way to fill your resume and bridge a gap from one position to the next, then, you know, maybe it's a couple of interim projects that you string together to show that you're doing some, quote, unquote, contractual project based work.

16:27That always is is more appealing than just having a gap. You're gaining new contacts, probably. Right? You're because you're interacting with acting with with new people. You may be like you said, you may be gaining experience in a new therapeutic area or building on an existing expertise in a certain therapeutic area. So for the individual, I think there's a lot of advantages to considering doing this.

16:58What would you say are the advantages for companies to consider doing these fractional type of projects? So one point before I address that question, and you you made me think of it as you were describing that, is that it it gives you as the potential candidate another solution to provide the company in that, okay. They're looking for a full time individual, but maybe you don't know exactly what all the

17:32conditions of that full time position. Maybe it's a company exploring the possibility of a full time position, and then they see in your resume, to your point, that you've you've added your your consultancy. Maybe you've established an LLC as as a as a corporate entity by which to to do this consultancy, and maybe it will broaden the discussion during the interview of, hey. Maybe we instead of a full time job, maybe we bring you in in a part time capacity and see

18:07how it works out before we lock and load into a full time equivalent. It it it broadens the company's perspective on how they're gonna get the work done. It may may not may not require a full time equivalent even though you're in the interview to have the possibility of this turning into a full time, job. So back to your question, what are the advantages, to the company? I think first and foremost, it's a cost effective measure for very specific project

18:45based work. So maybe the company's at a critical stage, and they know they need to get something done. This would traditionally be something that a medical director, would do or maybe a a head of medical affairs, but they're not quite ready to pull the trigger on bringing in, somebody at that level and so forth, but they know they need to get certain things done. This could be a very, very good cost effective way of making sure that those things, those

19:20critical milestone things in the evolution of the company get done without actually committing to a full time equivalent. So I think that's probably what's driving a lot of this. And I think if you look at the the current trend, there's been about a 300% increase in the use of fractional interim contract based expertise in the pharmaceutical, biotech, and med tech arena over the last couple years.

19:50I've I've recall seeing some of those statistics to that effect, and I think companies, because they're they're limited runway, I read somewhere that 40% of clinical stage companies have less than a year of funding. So you the companies who who start out, they do an IPO. They typically, you know, find a suite. They start building out the c suite, and and then they they start building the

20:20infrastructure from a talent perspective, and then they they start doing the critical work and so forth. I think a lot of, senior management CEOs and so forth are are thinking, how can we do it with less commitment to full time equivalents, less people? How how can we keep the process moving without really, you know, weighing ourselves down for lack of a better way of describing it with with the full compliments of of the talent that you

20:55would typically have when you start a company. Can we do it in an in an interim fashion? I'm I'm working with a an oncology company whose business model is really focused on delivering very specific tactical recommendations on drug design for big pharma, but they're also concurrently trying to develop their own drug.

21:25So what are they doing? And I think it's brilliant. This concurrent first time drug development, they're all interim consultants, fractional experts, whether it's an interim CMO, interim head of medical affairs, that's the role I play, interim translational medicine, interim regulatory, and so forth. So they have this whole kind of interim part of the company that's concurrently in tandem to

21:58all the other things that they're doing, developing this drug in parallel. And I think it's a really cost effective way of of continuing to evolve the company and and potentially seeing if they if they can go off on their own. Yep. Couple things to unpack. Kind of a scary statistic. 40% of companies are operating with less than a year of of capital. Definitely scary statistic.

22:29I'm gonna make a statement. I think that's gonna change. I think that the there's a lot of money sitting on the sidelines. Oh, there is. Tons of money sitting on the sidelines. I think that we should see that start to come from the sidelines onto the playing field, and there's gonna be a lot more opportunity coming up. Why do I say that? Because what goes up must come down and vice versa. The money's been sitting on the sidelines for a long time.

23:00Yeah. And I know that there was uncertainty with the election and, you know, what's Trump gonna do and, you know, what's gonna happen with these tariffs. And I know that there's been a lot of uncertainty, but as the stock market continues to go up and if interest rates finally come down, if there's other factors that maybe play into things I know that we we I don't wanna get into a political conversation because there's obviously a lot of uncertainty still. But I do think that at some point, these investors are gonna say, I need I need to get back into this, into this biotech market.

23:31We talked about advantages of these these fractional projects, both for individuals and for companies. The one thing I wanna point out as far as a disadvantage for the individual is that when you're looking for your next job, let's say you ultimately want a full time position, and you say, well, I'll take an interim. I'll take a three month gig. I'll take a six month gig.

24:02The only thing that I really wanna caution you about is that as you continue to interview for other positions, there's that timing factor. Mhmm. You're trying to to put the pieces together so that you transition from the fractional or the interim over to the the new job, which, you know, could be full time. But once you commit to doing a three month fractional, like, project, you know, it's kinda hard to to just back out on it without burning a lot of bridges.

24:34I mean, I guess you can be transparent with the person and saying, hey. I'm available. I wanna do this, but I'm also interviewing. So that's one thing. The other thing is you just have to maybe consider in the interview process, find out if they would be willing to accept a longer start date. So let's just say you get in through the final stages and they and you say, or even in the beginning stages. You know, would you be comfortable if I start in two months when I finish this assignment?

25:06Then at least, you know, upfront, you communicate that. What would you say disadvantages or maybe, the downsides for companies to go this route? Well, I think, the downsides is you're you're not fully committing to someone. And I I actually the more I think about it, Tom, I think there's a lot more upside for the

25:36company. The reason I'm saying that is in the companies that I've done this for, there's always been an upfront discussion. This could turn into a full time position. Right? If if all the conditions are right, if we if we get the next series of funding, if everything moves forward, if you obviously deliver the goods and and and we're happy with working with you and what you do and so forth and so on, it could lead to a full time job.

26:07So I really think there's tremendous upside. What what happens, and I know this firsthand, is you you bring in this fractional interim person, and you're kind of you're kind of isolated to a certain extent because the the rest of the organization looks at you you're a contractor, and they're not making a full investment in in getting to know you and and so forth and so on. So they're you're you're part of the team, but you're not fully part of the team and so forth.

26:41And and, you know, I deal with ambiguity. I'm very autonomous and and so forth and so on. So that doesn't, phase me and so forth. But then you don't get, you're not able to translate the institutional knowledge to the individual because they're just often oftentimes, it's not enough time, and the onboarding process is typically truncated and so forth and so on. So you're you're not, as an organization, getting the full, full capabilities of the

27:16individual because you're keeping that individual, really focused on the deliverable and so forth. So you probably are not getting, everything that that individual could bring to the table because you're keeping it very project specific. Does that answer your question? Yep. Yep. Absolutely. Yeah. What like, when you're looking at the I'm just curious in your experience and from what you've seen out there, is this lucrative from a compensation standpoint?

27:48Or or what should people expect? Should they expect that because it's interim and it's shorter term that there's more money to be made in that short period of time? Is there less money to be made? Like, how do how do how should somebody view the compensation piece to this? Like everything in lifetime, it depends. Okay. Right. And you need to be flexible. Now I think it's really important to figure out what your value is. Okay. And it's a simple way of doing that.

28:21Figure out what your your last full time position, you know, base pay, bonus, equity, fringe benefits, roll that all in, figure out an hourly rate. That's a very simple thing to do. I think it's important to communicate your value, especially when you're doing very strategic things or you're advising on protocol design and so forth and so on. But you here's the thing, Tom. You you need to be very flexible in terms of what the company is able to, to offer you.

29:00Now oftentimes, I will get what my my, my target hourly rate is, But other times, I may need to take equity. Right? Because the company doesn't have the, the full cash coffer at its disposal and so forth. And that's fine. You just work that into the contract or maybe a retainer based type of situation. Or maybe it's a a very nominal hourly rate with a caret at the end depending on the outcome of

29:39the deliverable and so forth. So it's it goes from a to z. You need to be very flexible. I think it's really important to to network with other consultants to find out what they are they are charging, especially if you're in the same particular area. Like, hey. What's the range at which you you operate for a particular deliverable? Say it's a strategic tactical plan for medical affairs.

30:09What are you typically charged and so forth? Mhmm. You just need to be very flexible. But really define what you're worth. Go into that, initial discussion, the contract negotiation, discussion with that, and you you kinda tease out how comfortable they are with that, if if they agree with that in in the value. If you have the bandwidth to do this, maybe it's instead of hourly, you do it on a daily

30:41basis, or you do it as a project basis as a lump sum and so forth. You take an upfront amount, and then you you invoice at the end of the project and so forth. So it's all these different factors need to be considered, and it's really important to be flexible with it. And the very simply, maybe taking less on an hourly rate may lead to the next project

31:11Right. Where you can justify a higher hourly rate, and they see what you're capable of, and they see the value that you bring to the organization. Yeah. And you your value can increase as they get comfortable with you, and they actually obtain the value that you you bring from your first, working with them. You know, it makes me think too. I know I'm gonna get this question, So I'm gonna get ahead of it right now and try to answer it. People are gonna say, what do I do if someone asks me what my rate is?

31:48Or what do I do if I don't wanna give my rate and I wanna kinda see what they're offering before I because we get this all the time. And one of the things I would recommend so, guys, if you're in that situation, what I would recommend, there's one question that you can ask that I think will help. Hopefully, they'll give you the answer because they don't always give you the answer. But if you say, help me to better understand your budget.

32:19Help me to better understand your budget. Hopefully, they'll give you an understanding of what their numbers are and how you might fit into it Yeah. As opposed to you saying, I make x amount of dollars an hour, or I need this much a month, or this much a week, or whatever it is. Do you see this continuing? Do you see this getting more popular? Is this a flash in the pan?

32:49So how do you look at fractional staffing, you know, over the course of the next, you know, several years? You look at the trajectory of things over the last couple years. I indicated earlier that there's been a 300 increase, and, you know, it only takes two data points to define a trend. If you have more than two, it it gets tighter and you you're you're more confident in in what that trend is actually going to predict and so forth.

33:20I think there's always going to be a place for this. I think it's especially getting a lot of attention right now because of the budgetary constraints a lot of companies are in, and they know that, things need to get done. So they're being rather resourceful and strategic with the way they're spending their money and so forth. So I think it'll always be there. To your point earlier, you know, at some point, the pendulum will swing back. But I think I think this is kind of a a learning process for pharma and biotech and med

33:56tech right now. I've heard this phrase. It's kind of an old phrase, the salad days, which is implies when everything is going swimmingly well. You know, money is not an issue. The future's so bright. We gotta wear shades. Farm is the where a lot of investors you despite the risk, they're putting their money and so forth. Well, that's not currently the case right now. If you look at big pharma right now, there's a lot of acquisition or not a lot, not nearly as

34:27many as there have been in the past. And the type of acquisitions have been rather late stage, which means just like the investors, pharma's looking for high probability of success and so forth. So I think these clinical stage companies have to figure out a cost effective way of getting to, data disclosure that will make them enticing to investors if they're publicly traded or big pharma who may be looking at it as an acquisition and so forth.

35:02Investors want to be assured that there's a strong probability that they're going to make it through and get the approval and have a differentiated product and so forth. And a lot of executive management CEOs are trying to figure out how to to do this with less money. So Mhmm. To your question, I actually think it's actually going to become more prominent or more prevalent with pharma, biotech, and med tech because they're realizing that they're

35:39continuing to move things forward but in a more cost effective way. You know, the days of building out the team and then setting about getting it, getting the work done, I think people are going to look back and going, you know, that that's a heavy spend. I think we can do this more cost effectively. So my prediction is that it's it's going to it's going to gradually keep notching up because there's a lot of talent out there.

36:13There's a lot of expertise. It's the gig economy of late, and I think companies are going to see this as a way of expanding their pipeline without making significant, talent investments, at least initially until they become commercial. That's my prediction. You heard it here first, folks. Daniel, thank you so much for sharing these insights. I think you know what? It's so funny. It's like you hear that term gig economy.

36:44That that's what this is. These fractional positions, they're gigs. So it it just goes to show that it is the thing, and it's probably not going anywhere anytime soon. I think that this is gonna stick around for a while. I agree. I agree with your prediction. So, Daniel, thank you for joining us. As always, you're the man. Appreciate all your all your great pearls of wisdom. Thank you so much, Tom. Always a pleasure to talk to you and your audience, and I I look for our next opportunity to have a chat. Yeah, man.

37:14And, guys, as always, thank you for joining us. And if you got value in this, please share the show. Comment on LinkedIn if you see some stuff out there, and, love you guys. We'll see you next time. Thanks, Seth.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. The Wrong Voices: How Bad Mentors Can Ruin Your Career

    Nov 17, 202628 minVideo

    What qualifies someone to influence your future? Tom Caravela explains why career guidance should be filtered through relevant experience, current knowledge, credibility, and objectivity. He examines the risks of...

    Listen to the audio

    Credit the people on this episode

  2. Hidden Secret to Career Happiness and Longevity

    Nov 3, 202635 minVideo

    What turns an industry contact into a long-term ally? In this episode, Tom Caravela and Ed Doherty look beyond transactional networking to the genuine friendships that can shape a career in medical affairs. They discuss...

    Listen to the audio

    Credit the people on this episode

  3. How to AI-Proof Your Career: The 4 Pillars of Career Success

    Oct 20, 202623 minVideo

    Becoming undeniable is Tom Caravela’s answer to building career security in the age of AI. He breaks down four pillars you can control: skills, experience, relationships, and brand. Tom explains how continuous learning...

    Listen to the audio

    Credit the people on this episode

  4. How Medical Affairs Influences Decisions that Matter

    Oct 13, 202638 minVideo

    What happens after an MSL submits an insight? In this episode, Tom Caravela and Cameron Tew examine how field observations create value only when organizations decide what to do next. They discuss shared definitions,...

    Listen to the audio

    Credit the people on this episode

  5. Stop Being Your Own Worst Enemy

    Sep 29, 202619 minVideo

    In this episode, Tom Caravela discusses common mindset traps that can hold Medical Science Liaisons and aspiring MSLs back. He covers how to move past worst-case thinking, overanalysis, concern about others’ opinions,...

    Listen to the audio

    Credit the people on this episode